KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Short term Debt (2016 - 2025)

Pacira BioSciences has reported Short term Debt over the past 14 years, most recently at $202.4 million for Q2 2025.

  • Quarterly results put Short term Debt at $202.4 million for Q2 2025, changed N/A from a year ago — trailing twelve months through Jun 2025 was $202.4 million (changed N/A YoY), and the annual figure for FY2024 was $201.8 million, up 2235.1%.
  • Short term Debt for Q2 2025 was $202.4 million at Pacira BioSciences, roughly flat from $202.1 million in the prior quarter.
  • Over the last five years, Short term Debt for PCRX hit a ceiling of $350.5 million in Q4 2021 and a floor of $8.6 million in Q2 2023.
  • Median Short term Debt over the past 5 years was $153.7 million (2021), compared with a mean of $123.9 million.
  • Biggest five-year swings in Short term Debt: crashed 93.22% in 2023 and later surged 2238.69% in 2025.
  • Pacira BioSciences' Short term Debt stood at $350.5 million in 2021, then tumbled by 90.4% to $33.6 million in 2022, then plummeted by 74.32% to $8.6 million in 2023, then skyrocketed by 2235.1% to $201.8 million in 2024, then increased by 0.31% to $202.4 million in 2025.
  • The last three reported values for Short term Debt were $202.4 million (Q2 2025), $202.1 million (Q1 2025), and $201.8 million (Q4 2024) per Business Quant data.